SINKULE JOSEPH 4

What Happened Joseph Sinkule, CEO of Klotho Neurosciences (KLTO), was granted 2,500,000 shares (transaction code A) on 2026-03-04. The grant is recorded as an award — no purchase price or cash exchanged is reported (price = N/A), so the filing does not state a total market value for the award.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (accession 0001213900-26-024574).
• Transaction type/code: Award/Grant (A).
• Shares acquired: 2,500,000.
• Price per share: N/A (award/grant; no cash purchase).
• Shares owned after transaction: not specified in this filing.
• Footnote: F1 — shares were received as a grant under the company’s Equity Incentive Plan.
• Timeliness: Form 4 was filed two days after the transaction date, which appears timely under standard Form 4 rules.

Context Equity grants are typically compensation and are often subject to vesting schedules and other restrictions; they do not by themselves indicate a CEO buying or selling shares in the open market. Retail investors should watch for future Form 4s that report vesting, exercises, or sales and review the company’s equity plan disclosures for details.